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Abstract:  Fourier  domain  low  coherence  interferometry  (fLCI)  is  an 
emerging  optical  technique  used  to  quantitatively  assess  cell  nuclear 
morphology in tissue as a means of detecting early cancer development. In 
this  work,  we  use  the  azoxymethane  rat  carcinogenesis  model,  a  well 
characterized  and  established  model  for  colon  cancer  research,  to 
demonstrate  the  ability  of  fLCI  to  distinguish  between  normal  and 
preneoplastic  ex-vivo  colon  tissue.  The  results  show  highly  statistically 
significant  differences  between  the  measured  cell  nuclear  diameters  of 
normal and azoxymethane-treated tissues, thus providing strong evidence 
that fLCI may be a powerful tool for non-invasive, quantitative detection of 
early changes associated with colorectal cancer development. 
©2010 Optical Society of America 
OCIS  codes:  (120.3180)  Interferometry;  (290.1350)  Backscattering;  (170.4500)  Optical 
coherence tomography; (300.0300) Spectroscopy. 
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1. Introduction 
Colorectal cancer (CRC) is the third most common cancer and the third leading cause of 
cancer death in men and women in the United States [1]. As is commonly known, the most 
successful practice for preventing cancer mortality is to regularly screen people at risk. This is 
particularly important for CRC since the disease is largely asymptomatic until it has reached 
an advanced stage; fortunately, if diagnosed early, the survival rate dramatically improves. 
Today, the gold standard for screening CRC is conventional colonoscopy, which relies on 
visual inspection through an endoscope to detect polyps and adenomas. Once identified, the 
decision to remove these mucosal growths is based on size, where it is recommended that 
lesions >5 mm in diameter be removed [2]. This approach, however, suffers from serious 
weaknesses: 1. There is no reliable metric for determining whether lesions are adenomatous 
or metaplastic; hence, the decision to remove these lesions is left to the discretion of the 
physician.  Note  that  approximately  90%  of  all  cases  of  CRC  originate  through  benign 
adenomas [2]. 2. Despite the fact that small lesions (<5 mm) are not typically removed, some 
studies have presented evidence that these are very likely to contain neoplasias, particularly 
for lesions proximal to the left colon [3]. 3. Flat adenomas, which are ten times more likely to 
contain malignancy compared to similarly sized polyps, appear similar to the surrounding 
tissue, and are consequently  very difficult  to detect  with  colonoscopy [4]. 4. Because all 
detected  polyps  are  considered  adenomatous  [2],  many  unnecessary  biopsies  and 
polypectomies are preformed,  which increase the probability of complications [5]. Lastly, 
while other screening tests are available, including fecal occult blood test, sigmoidoscopy, and 
virtual colonoscopy, these are more limited and less effective; further, in the event that an 
abnormality is detected with these alternative screening tests, patients must then undergo a 
colonoscopy [6]. 
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that  assess  tissue  health  quantitatively  and  in  a  minimally  invasive  manner.  To  this  end, 
biomedical optics has emerged as a promising field, in which various techniques have been 
developed to probe different biomarkers accessible via optical absorption and/or scattering 
measurements. For example, 4-dimensional elastically scattered light fingerprinting (4D ELF) 
[7] and diffuse reflectance spectroscopy [8] have been able to quantify tissue hemoglobin 
concentration  as  a  surrogate  biomarker  for  malignancy.  Further,  low-coherence  enhanced 
backscattering  spectroscopy  (LEBS)  [9]  and  angle-resolved  low  coherence  interferometry 
[10] have retrieved information regarding nano- and micro- tissue morphology, thus providing 
insight to precancerous states. 
In this paper, we present an application of an emerging optical technique, namely Fourier 
domain  low  coherence  interferometry  (fLCI),  to  measure  early  CRC  changes  using  an 
analysis of ex-vivo tissues drawn from the azoxymethane (AOM) rat carcinogenesis model. 
fLCI measures oscillatory features in depth resolved spectra, also known as local oscillations, 
which result from coherent fields induced by the scattering by the front and back surfaces of 
cell nuclei in tissue [11]. Thus, fLCI uses nuclear morphology as a biomarker of disease, 
making  it  sensitive  to  the  earliest  stages  of  precancerous  development.  To  achieve  depth 
resolved  spectroscopic  analysis,  we  use  the  dual  window  (DW)  method,  which  obtains 
simultaneously high spectral and depth resolution, and yields access to the local oscillations 
[12]. Further, fLCI signals can be processed to yield cross sectional images of samples, as in 
Fourier  domain  optical  coherence  tomography  (FD-OCT)  [13],  thereby  enabling  co-
registration of the structural information with the spectroscopic analysis. The capabilities of 
fLCI using the DW method have been demonstrated using scattering phantoms [14] and ex-
vivo  samples  from  a  hamster  cheek  pouch  model  [11].  Here,  we  use  fLCI  to  provide  a 
spatially resolved, functional analysis of ex-vivo tissue samples at three depths and along two 
different  sections  of  the  left  colon  to  demonstrate  fLCI’s  ability  to  detect  early  CRC 
development. 
2. Materials and methods 
2.1 Animal model 
This study used the  AOM rat carcinogenesis  model, a  well characterized and established 
model for colon cancer research and drug development [15]. The cancerous progression of 
this model is similar to that seen in humans and is a good surrogate for human colon cancer 
development. In addition, the short induction period and high incidence of aberrant crypt foci 
(ACF), which are preneoplastic lesions [16], make this model a practical choice for testing the 
ability of fLCI to detect precancerous development in the colon. 
All animal experimental protocols were approved by Institutional Animal Care and Use 
Committee of The Hamner Institute and Duke University. Forty F344 rats (six-week old, 
male; Charles River Laboratories Inc., Kingston, NY) were housed in The Hamner’s animal 
facility for a 10-day acclimation period prior to any testing. All the animals were provided 
with a regular National Institutes of Health-07 diet (Ziegler Brothers, Gardners, PA) for the 
first 4 days of acclimation. Thereafter, the diet was switched to the pellet form of American 
Institute of Nutrition (AIN)-76A (Dyets Inc., Bethlehem, PA) and continued for the rest of 
study period. Two animals per cage were housed in polycarbonate, solid-bottom cages with 
Alpha-dry bedding in an animal room with a 12-hr light/dark cycle. Cages were changed 
twice  a  week.  Pelleted,  semipurified  AIN-76A  diet  and  water  were  available  ad  libitum. 
Weekly body weights were collected during the whole study period, and clinical observations 
were performed to monitor the health of the animals. 
After  10  days  of  acclimation,  the  40  rats  were  randomized  into  groups  of  10.  Thirty 
animals  received  intraperitoneal  (IP)  injections  of  AOM  >90%  pure  with  a  molar 
concentration of 13.4 M (Sigma, St. Louis MO) at a dose level of 15 mg/kg body weight, once 
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saline by IP and served as the control group. At 4, 8, and 12 weeks after the completion of the 
dosing regimen, the animals (10 AOM-treated and 3 or 4 saline-treated rats per time point) 
were  sacrificed  by  CO2  asphyxiation.  The  colon  tissues  were  harvested,  opened 
longitudinally,  and  washed  with  saline.  Then,  the  tissues  were  split  into  4-5  different 
segments, each with a length of 3-4 cm. Only the two most distal segments of the colon were 
analyzed for these experiments: the distal left colon (LC) and proximal LC. Then, the samples 
were placed on a cover glass for examination with the parallel frequency domain OCT system 
(see  Section  2.2).  Finally,  the  tissue  samples  were  fixed  in  formalin  and  stained  with 
methylene blue in order to be scored based on the number of ACF, which are defined as foci 
containing more than two aberrant crypts. Figure 1 shows an image of a stained tissue sample, 
4 weeks post treatment with three ACF that contain 2, 3, and 4 aberrant crypts. 
 
Fig. 1. Stained tissue sample, 4 weeks post treatment with three ACF containing 2, 3, and 4 
aberrant crypts. 
2.2 Detection system 
The system used is a parallel frequency domain OCT (pfdOCT) system [17], which consists 
of  a  Michelson  interferometer  geometry  with  the  addition  of  four  lenses  that  form  a  4-F 
interferometer [18]. Using lenses L2 and L3 as seen in Fig. 2, the multimode fiber-coupled 
light from a Xe-arc lamp (150 W, Newport Oriel, Stratford, Connecticut) is collimated onto a 
sample.  The  samples  are  placed  atop  a  #0  cover  glass,  which  is  tilted  slightly  to  avoid 
saturation from specular reflection by the glass-air interface and thus allowing detection of 
only the scattered light. This is known as scatter mode imaging. For the ex-vivo colon tissue, 
the lumen side was placed facing down (against the cover glass), since the light illuminates 
from below the sample as seen in the inset of Fig. 2. Then, using L3 and L5, light scattered 
from a sample is imaged onto the entrance slit of an imaging spectrograph (SP2156, Princeton 
Instruments, Trenton, NJ). The reference arm follows a similar optical path, with lenses L2 
and  L4,  and  L4  and  L5.  After  light  is  dispersed  into  its  wavelength  components  by  the 
spectograph, the interference between the sample and reference fields is recorded using a 
CCD camera (Pixis 400, Princeton Instruments, Trenton, NJ). Detection is centered about 600 
nm  with a bandwidth of 240 nm. This configuration allows  for 201 interferograms to be 
collected simultaneously (limited by the beam width), yielding B-mode OCT images from a 
single exposure. 
For this particular configuration, the system underwent slight modifications compared to 
previous  system  implementations  reported  in  [11,14,17]. First,  a  2X  magnification  of  the 
sample field at the spectrometer slit was achieved by setting the focal length of L3 and L4 
equal to 50 mm, and that of L2 and L5 equal to 100 mm; with a pixel size of 20 µm, this 
resulted in a lateral resolution of 10 µm. The use of shorter focal length lenses also allowed 
for the total footprint of the system to be reduced, ultimately allowing the system to be made 
portable. Portability is achieved by placing the system inside a 8”X18”X24” custom made 
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analysis of tissue samples. 
 
Fig. 2. Parallel frequency domain OCT system operating in scatter mode. 
2.3 Data processing 
The fLCI process for assessing cell nuclei diameter involves multiple steps. The first step is to 
obtain OCT images of the samples. Next, spatially resolved spectra are calculated using the 
DW method. Then, the spatial information provided by the OCT images is used to co-register 
the  spectroscopic  information;  this  allows  for  the  spectra  to  be  consistently  analyzed  at 
specific tissue depths. Finally, spectra from specific regions within the tissues are averaged to 
yield  spectral  oscillations  that  reveal  cell  nuclear  diameters.  In  this  section  we  provide  a 
detailed procedure of these steps. 
To obtain OCT images, the initial step is to digitally remove the DC background from the 
interferometric signal using separate acquisitions of the sample arm, reference arm, and dark 
signal. Then, the interferometric data are normalized by the reference arm intensity to remove 
any  spectral  dependence  originating  from  the  source  and  detector  efficiency.  The 
interferograms are then resampled from wavelength to a linear wavenumber vector (k = 2π/λ), 
and digitally corrected for chromatic dispersion [19]. Subsequently, the signals are Fourier 
transformed to obtain OCT images with an axial resolution of ~1.10 µm (experimental). A 
refractive index (RI) of n = 1.38 is used to convert the optical path length to physical axial 
distance in tissue [20]. Figure 3 illustrates a representative image of an ex-vivo rat colon 
sample. 
 
Fig. 3. pfdOCT image of an ex-vivo rat colon sample. The red line delineates an example 
region that is averaged across to determine the nuclear diameter. 
To  obtain  depth-resolved  spectroscopic  information,  the  DW  method  is  used  [12].  As 
illustrated  in  Fig.  4,  the  method  consists  of  multiplying  two  STFTs  that  operate  on  each 
interferogram. A STFT is implemented by sweeping a window across the interferometric data 
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content confined within a spatial (or axial) region. These maps are known as time-frequency 
distributions (TFDs). However, TFDs obtained using a single STFT suffer from an inherent 
trade-off between the resulting spectral and spatial resolutions. The DW method, on the other 
hand, utilizes the high spectral resolution of a STFT using a narrow window, and the high 
spatial resolution of a STFT using a wide window to avoid the deleterious effects of the time-
frequency trade-off [12]. Here, Gaussian windows were used with standard deviations w1 = 
0.029 µm
−1 and w2 = 0.804 µm
−1, resulting in TFDs with an axial resolution of 3.45 µm and 
spectral resolution of 1.66 nm. Note that this process is  conducted for each  A-scan, thus 
giving a spectrum for each point in an OCT image. 
The  last  step  to  obtaining  spectral  information  from  specific  tissue  depths  (i.e.,  local 
oscillations) is to co-register the OCT images with the DW TFDs. This process involves using 
the images to identify the contour of the tissue surfaces and calibrate the analysis relative to 
this ’zero’ depth. Note that if a surface is not clearly discernable at any particular A-scan, no 
further analysis is conducted there. With this information, the DW TFDs can be properly 
aligned and thus consistently provide spectral information from specific tissue depths. 
 
Fig. 4. DW processing method to obtain TFDs with simultaneously high spectral and spatial 
resolution. Two STFTs, one obtained with a narrow window and another with a wide window, 
are multiplied together to obtain the DW TFD. Gaussian windows were used with standard 
deviations w1 = 0.029 µm
−1 and w2 = 0.804 µm
−1, resulting in TFDs with an axial resolution of 
3.45 µm and spectral resolution of 1.66 nm. 
Once the spectra are properly aligned, regions of interest, both laterally and axially, are 
identified and averaged in order to provide sufficient signal-to-noise ratio for the spectral 
analysis  that  follows. In  the  lateral direction, twenty DW TFDs are averaged to yield 10 
different lateral segments in each OCT image. Note that in previous studies all TFDs in an 
image were averaged [11]; thus, the analysis provided here produces a 10-fold increase of the 
spatial information. In the axial direction, we calculate the spectral averages of 25 µm depth 
segments from three different sections: at the surface (surface section 0-25 µm), centered 
about 35 µm in depth (mid section. 22.5-47.5 µm), and centered about 50 µm in depth (low 
section 37.5-62.5 µm). The area inside the red dotted line in Fig. 3 gives an example of a 
resulting mid section from which the spectra are averaged to determine the nuclear diameter. 
The spectra from the averaged regions contain two components. The first component is 
the  low  frequency  oscillations  that  have  been  associated  with  the  periodic  fine  structures 
induced by spherical scatterers, which have been analyzed previously using the van de Hulst 
approximation in light scattering spectroscopy (LSS) [14,21–23]. The approximation gives an 
analytical solution to the scattering cross section of spherical scatterers, which tells us that the 
periodicity of the spectral oscillations depends on size, as well as on the ratio between the RI 
of  the  scatterer  and  surrounding  medium  [23].  This  ultimately  results  in  relatively  low 
frequency oscillations. However, we have found that due to the lack of knowledge of the 
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that  can  be  extracted  from  the  LSS  method  is  limited.  Therefore,  the  low  frequency 
oscillations  are  isolated  using  a  smoothing  function  in  MATLAB  (Mathworks,  Natick, 
Massachusetts) and subsequently removed from the spectra. This process isolates the second 
component:  the  high  frequency  oscillations  of  the  spectra,  which  correspond  to  the  local 
oscillations resulting from coherent fields induced by the cell nuclei in the averaged region. 
Unlike the periodic fine structures in LSS, the local oscillations only depend on the size and 
RI of the scatterer, thus resulting in higher frequencies. Specifically, the periodicity of the 
local oscillations is given by the sample field’s round trip optical path length ( OPL) thought 
the scatterer, and is related to the scatter size (in this case, dc) by dc =  OPL/(2nn), where nn is 
the RI of the cell nuclei. Figure 5(a) illustrates the average spectrum (solid blue line) along 
with the isolated low frequency component (dotted black line) for the averaged region shown 
in Fig. 3. Figure 5(b) shows the resulting local oscillations. 
Finally,  a  Fourier  transform  of  the  local  spectral  oscillations  is  taken  to  produce  a 
correlation function, where we attribute the peak in this function to indicate the average cell 
nuclear  diameter  in  the  region  of  analysis  [11].  Other  scatterers,  such  as  other  cellular 
organelles and nuclear content,  may also produce peaks in this function, but due to their 
random orientation, size, and spacing with one another, the resulting signal is unlikely to 
produce  a  peak  greater  in  magnitude  than  that  of  the  average  cell  nuclear  diameter.  The 
correlation function for the local oscillations in Fig. 5(b) is shown in Fig. 5(c), where the 
correlation distance (dc) has been properly scaled to account for the round trip optical path 
length and the RI of the cell nuclei. We assumed a constant nuclear RI of nn = 1.395 for this 
analysis [20]. As a last step, the peak detection process is automated to enable analysis of 
large data sets. To achieve this, the correlation function is subject to further processing, where 
the 1/f noise is removed using a smoothing function. Then, only maxima that are 3.5 standard 
deviations above the mean of the correlation function are considered to be clear peaks. If this 
criterion is not met at any particular region, the measurement is discarded. 
 
Fig. 5. Average spectrum (blue solid line) from the delineated region in Fig. 3, along with low 
frequency component (black dotted line) (a). The low frequency component is subtracted from 
the  averaged  spectrum  of  obtain  the  local  oscillations  (b).  A  Fourier  transform  yields  a 
correlation function (c), where the peak corresponds to an average cell nuclear diameter of 7.88 
µm in the region of analysis. 
3. Results 
3.1 Depth sections 
The nuclear diameters from the three different tissue depth sections and for all time points are 
summarized in Fig. 6 and Table 1. We note that the control group measurements of all the 
time points were combined, since no statistically significant differences were found between 
them. Statistical tests were conducted using a two-sided student t-test. 
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Fig. 6. Nuclear diameter by depth sections. The mid section (35 µm in depth) provided the 
most significant results, with p-values<10
−4 ** for the treated samples at all time points when 
compared to the control group. No statistical significance was found at the surface, and mildly 
significant differences (p-values <0.05 *) were found at the low (50µm) section. 
As shown in Fig. 6, the mid section (35 µm depth) provided the most significant results, 
where the treated groups at all three time points yielded p-values<10
−4 ** when compared to 
the control group. The fLCI measurement for the control group at the mid section yielded an 
average cell nuclear diameter of 5.15+/−0.05 µm, while for the treated groups it was found to 
be  5.91+/−0.15  µm,  6.02+/−0.18  µm,  and  6.49+/−0.49  µm  at  4,  8,  and  12  weeks  after 
treatment,  respectively.  For  the  deepest  (low,  50  µm  depth)  section,  mildly  statistically 
significant  results  were  observed,  with  p-values<0.05  *.  At  the  surface,  however,  no 
statistical significance was found. 
Table 1. Measured cell nuclear diameter by depth sections 
  Surface (mean+/− − − −SEM)  Mid (mean+/− − − − SEM)  Low (mean+/− − − − SEM) 
Control  5.88+/− 0.20  5.15+/−0.05  5.25+/−0.05 
Week 4  5.96 +/− 0.18  5.91+/−0.15**  5.84+/−0.16* 
Week 8  6.36 +/− 0.21  6.02+/−0.18**  5.97+/−0.18* 
Week 12  5.48 +/− 0.33  6.49+/−0.49**  5.95+/−0.47* 
All measurements in µm; p-values<10
− − − −4 **; p-values<0.05 *; N = 10. 
3.2 Length segments 
The two tissue segments (proximal and distal left colon) were further analyzed separately for 
the  mid  depth  section.  The  measured  cell  nuclear  diameters  and  number  of  ACF  are 
summarized in Table 2. We found that for all the time points, and for both segments, the 
measured  nuclear  diameters  for  the  treated  groups  were  significantly  different  from  the 
control group (p-values<10
−4 **). 
The results are also summarized in Figs. 7(a) and 7(b). Note that significant differences 
were observed for both segments after only 4 weeks post treatment. The measured increase in 
the nuclear diameter, however, remained relatively constant thereafter, with the exception of 
the last time point in the proximal LC. Here, the nuclear diameter increased dramatically from 
~6.0 µm to ~7.2 µm. To investigate this further, Fig. 7(c) plots the nuclear diameter as a 
function of the average number of ACF, which are preneoplastic lesions. For clarity, we also 
identify each point with its corresponding time period. Note that the formation of ACF was 
faster in the proximal LC compared to the distal LC, and that the plot shows a region of little 
nuclear  morphological  change  after  the  initial  formation  of  ACF.  This  plateau  region  is 
present in both sections and is initially independent of the number of ACF. However, once the 
number of ACF increased to the maximum value observed in this study (~70), the measured 
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neoplastic  development,  in  contrast  to  the  ubiquitous  and  relatively  constant  cell  nuclear 
diameter measurements of the plateau region. 
Table 2. Measured cell nuclear diameter (fLCI measurement) and number of ACF by 
length segments 
  Proximal LC (mean+/− − − −SEM)  Distal LC (mean+/− − − −SEM) 
  fLCI [µm]  ACF  fLCI [µm]  ACF 
Control  5.15+/−0.05  0  5.15+/−0.05  0 
Week 4  5.87+/−0.19  13.4+/−3.64  5.98+/−0.26  5.9+/−1.33 
Week 8  5.88+/−0.27  55.1+/−5.60  6.14+/−0.24  16+/−1.71 
Week 12  7.23+/−1.21  68.6+/−4.74  6.10+/−0.39  33.3+/−5.95 
  all p-values<10
− − − −4 **; N = 10. 
 
Fig. 7. Results by colon length segments. Highly statistical differences (p-value <10
−4 **) were 
observed between the control group and treated groups for the proximal LC (a) and distal LC 
(b). (c) Plots the measured cell nuclear diameter as a function of the number of ACF. For 
clarity, the time of measurement is noted next to each point (wk = week). 
4. Discussion 
The results, presented in Section 3.1, highlight the importance of obtaining spatially resolved 
information for assessing tissue health. Other optical methods have also demonstrated the 
need for depth selectivity, but the specific depth that provides the most diagnostic information 
has varied. Using LEBS, which assesses changes in tissue nano-architecture, it was found that 
a penetration depth of 70 µm yielded the most significant results [9]; whereas using 4D ELF 
to measure hemoglobin concentrations, a penetration depth of 100 µm was found to yield 
significant results [7]. With these optical methods, however, useful information is obtained by 
integrating to a particular depth, rather than sampling specific locations, which may explain 
the differences. In contrast, fLCI is an interferometric technique that uses a broadband source, 
and thus enables the coherence gating imaging capabilities of OCT and allows sampling of 
specific points in three-dimensional space. Image guidance was vital in this study in order to 
identify the tissue surface and probe specific tissue depths. 
Along with the imaging capabilities of fLCI, the DW method is an equally important 
feature to enable this study. The DW method avoids the spectral and spatial resolution trade-
off  that  has  hindered  quantification  using  STFTs  or  continuous  wavelet  transforms. 
Acquisition of the local oscillations necessitates high resolution in both dimensions, otherwise 
the  phenomenon  of  fringe  washout,  resulting  from  phase  and  frequency  differences  from 
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diameter is assessed. 
In Section 3.2, the results were analyzed by segments along the length of the colon. Here, 
fLCI detected significant changes in segments and at time points that presented early evidence 
of  preneoplastic  development,  underscoring  the  sensitivity  of  the  method.  Further,  the 
measured  early  nuclear  morphological  change  was  observed  in  both  segments  and 
independently  of  the  number  of  ACF,  which  suggests  a  ubiquitous  micromorphological 
change of the colon. This, however, was not the case when neoplastic development became 
more advanced (demarcated by the high number ACF); at which point, the nuclear diameter 
increase was specific to the affected region. These sets of results present significant findings: 
First, these results suggest that fLCI may be able to detect the “field effect” of carcinogenesis. 
This phenomenon describes observations that neoplastic development in one part of the colon 
distorts nano- and micro- tissue morphology, as well as tissue function, along the entire organ. 
This has been a subject of much interest since it indicates that adequate screening may be 
achieved by only probing certain (and more readily accessible) sections of the colon [7,9,25]. 
These  results  also  indicate  that  fLCI  can  identify  specific  regions  where  more  advanced 
neoplastic development has occurred, which is paramount for detecting CRC development 
and initiating a localized therapy. 
While the results presented here are very promising, there are certain limitations that still 
need to be explored in order to take advantage of all the information provided by the method. 
As  described  in  Section  2.3,  the  procedure  for  obtaining  fLCI  measurements  assumes  a 
constant  RI  value  for  the  cell  nuclei,  and  a  different  constant  value  for  the  bulk  tissue; 
however, it is known that the RI can vary depending on tissue type and tissue health. Thus, 
these variations, which are currently not assessed with our method, may be introducing an 
additional degree of uncertainty in the calculated nuclear diameters. Further, these variations 
have hindered our ability to use the low frequency oscillations with LSS, as we have done 
previously using tissue phantoms [14]. However, we believe that a more rigorous treatment of 
the LSS fitting algorithm may provide insight to the variations of the RI in future analyses. 
5. Conclusion 
In this study, we have used an AOM-treated rat model to demonstrate the ability of fLCI to 
quantitatively distinguish between ex-vivo colon tissue that is normal and that which exhibits 
early precancerous development. The results show highly statistically significant differences 
between the AOM-treated and control group samples. Further, the results suggest that fLCI 
may  be  able  to  detect  changes  due  to  the  field  effect  of  carcinogenesis,  in  addition  to 
identifying areas where more advanced neoplastic development has occurred. Future work 
will be directed towards developing an optical fiber based pfdOCT system to demonstrate 
non-invasive, in-vivo early CRC detection. 
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